PyroGenesis Canada and Syros Pharmaceuticals Compared

A head-to-head review of the two companies' financials and operations

Feb. 21, 2026 at 9:50am

Got story updates? Submit your updates here. ›

This article compares the financial performance and business operations of PyroGenesis Canada and Syros Pharmaceuticals, two publicly traded companies in different industries. The analysis looks at metrics like revenue, earnings per share, valuation, institutional ownership, and stock volatility to assess the relative strengths of the two firms.

Why it matters

The comparison provides investors with a data-driven analysis to help them evaluate the investment potential of these two companies and make more informed decisions about allocating their capital.

The details

PyroGenesis Canada has higher revenue and earnings than Syros Pharmaceuticals, and is trading at a lower price-to-earnings ratio, indicating it may be the more affordable of the two stocks. PyroGenesis also has a lower stock beta, meaning its shares are less volatile than the overall market. However, Syros has much stronger institutional ownership, which can signal long-term growth potential. Overall, PyroGenesis outperforms Syros on 7 of the 11 factors compared.

  • The financial data and analysis is current as of February 21, 2026.

The players

PyroGenesis Canada Inc.

A Canadian company that designs, develops, manufactures, and commercializes plasma processes and solutions for various industries, including defense, metallurgy, mining, and environmental.

Syros Pharmaceuticals, Inc.

A biopharmaceutical company focused on developing treatments for hematologic malignancies, with lead product candidates in clinical trials for myelodysplastic syndrome, acute myeloid leukemia, and solid tumors.

Got photos? Submit your photos here. ›

The takeaway

This analysis highlights the differing strengths of PyroGenesis Canada and Syros Pharmaceuticals, with PyroGenesis showing stronger financial performance but Syros having greater institutional backing. Investors will need to weigh these factors along with the companies' respective business models and growth prospects to determine which stock may be the better investment.